Sorafenib was found to inhibit B-Raf, Raf-1, and kinase activity in the Ras/Raf/MEK/ERK signaling pathways, thereby suppressing tumor cell proliferation, and exhibiting anti-angiogenesis and antiproliferation properties [10, 11]. This evidence concerns the gene RAF1 and neoplasm.